Portfolio yield
Data as at : 30/06/2026
| % |
|---|
| 0.8 |
Please note that the above fields are displayed for companies that have reported this data to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 30/04/2026
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 11.7 |
| AstraZeneca PLC | 6.0 |
| Boston Scientific Corp | 5.0 |
| Intuitive Surgical Inc | 4.3 |
| Roche Holding AG Ordinary Shares new | 4.2 |
| Merck & Co Inc | 4.0 |
| Edwards Lifesciences Corp | 3.9 |
| argenx SE ADR | 3.8 |
| Novo Nordisk AS Class B | 3.6 |
Geographic breakdown
Data as at : 30/06/2026
| Country | % of total assets |
|---|---|
| USA | 64.4 |
| Switzerland | 8.3 |
| UK | 7.3 |
| Netherlands | 4.3 |
| China | 4.0 |
| Belgium | 2.0 |
| Japan | 1.6 |
| France | 1.5 |
| Denmark | 1.5 |
| Canada | 1.2 |
| Hong Kong | 0.7 |
| India | 0.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 30/06/2026
| Industry | % of total assets |
|---|---|
| Healthcare | 95.2 |
| Cash Equivalents | 2.6 |
| Preferred | 1.9 |
Asset breakdown
Data as at : 30/06/2026
| Asset | % of total assets |
|---|---|
| Stock | 97.0 |
| Other | 0.3 |
| Cash/Cash equivalents | 2.6 |
Detailed asset breakdown
Data as at : 30/06/2026
| Asset | % of total assets |
|---|---|
| North America - stock | 69.7 |
| Europe - Large-cap stock | 10.4 |
| UK - Large core/growth stock | 7.3 |
| Europe - Mid-cap stock | 3.2 |
| Asia (excl Japan) - stock | 2.8 |
| Cash | 2.6 |
| Preferred stock | 1.9 |
| Japan - stock | 1.6 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.